Lutetium Lu 177 dotatate
Radiolabeled somatostatin analog for gastroenteropancreatic NETs.
What it is
Lutetium Lu 177 dotatate (Lutathera) is a radiolabeled somatostatin analog FDA-approved in 2018 for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The molecule combines a somatostatin analog with the radioactive isotope lutetium-177.
Mechanism of action
The somatostatin analog component binds somatostatin receptors expressed on neuroendocrine tumor cells. The targeted lutetium-177 then delivers radiation directly to receptor-expressing cells, providing peptide receptor radionuclide therapy (PRRT). This is a form of targeted radiotherapy.
Approved indications
Somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Why this is out of scope at The Tide
Highly specialized oncology medication requiring administration in nuclear medicine settings with appropriate radiation safety infrastructure. Use is coordinated by oncology, nuclear medicine, and specialized neuroendocrine tumor programs.
Where to learn more
Medical oncology, particularly programs specialized in neuroendocrine tumors.